News and Activities
Hot Off The Press.
Press Releases
MaRS’ SVX investing platform matches Proteocyte Diagnostics with Freycinet Investments
Toronto, ON; September 10, 2014 - Proteocyte Diagnostics Inc., a company with a unique test for early identification of oral cancers, today announced an investment by Freycinet Investments, made possible by MaRS’ SVX (Social Venture Connexion) impact investing platform. “We were pleased to see...
Proteocyte Diagnostics initiates a Cost-Effectiveness Analysis with support from Mitacs
Toronto, ON; August 29, 2014 - Proteocyte Diagnostics Inc. of Toronto announced their collaboration with Mitacs Accelerate to conduct an economic evaluation of its predictive technology for the early detection of oral cancer. “We’ve partnered with Mitacs before with great success,” said Dr. Mario...
Proteocyte Diagnostics closes $605,000 in funding
Toronto, ON; August 13, 2014 Proteocyte Diagnostics Inc. of Toronto today announced funding closed in the amount of $605,000 CDN including investments from Ontario Centres of Excellence (OCE) and a private syndicate of investors. “We are delighted with the support and investment by OCE and our...
Proteocyte Diagnostics joins MaRS’ SVX impact investing platform
Toronto, ON; July 16, 2014 - Proteocyte Diagnostics, a company with a unique test for early identification of oral cancers, announced today that it has officially joined MaRS’ SVX (Social Venture Connexion). Proteocyte Diagnostics Inc. is a Canadian molecular diagnostics company that has developed...